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Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is now frequently used in early clinical trial assessment of
antiangiogenic and vascular disrupting compounds. Evidence of drug efficacy and dose-dependent response has been demonstrated
with some angiogenesis inhibitors. This review highlights the critical issues that influence T1-weighted DCE-MRI data acquisition and
analysis, identifies important areas for future development and reviews the clinical trial findings to date.
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ANGIOGENESIS: A TARGET FOR ANTICANCER
THERAPY
In order to survive and grow beyond a few hundred micrometers,
tumours require adequate oxygen and nutrient delivery, as well
as removal of waste products. Angiogenesis, the process by which
tumours develop a circulatory blood supply, results in the
development of vascular networks that are both structurally and
functionally abnormal. Compounds that disrupt new vessel
formation (antiangiogenic) or destroy existing vessels (vascular
disrupting) offer potential targets for novel anticancer therapy
(Baluk et al, 2005). This strategy has been validated by recent
studies of the anti-vascular endothelial growth factor (VEGF)
antibody bevacizumab, which have shown improvement in clinical
outcome in phase III randomised-controlled trials in colorectal
(Hurwitz et al, 2004) and other common human cancers.
Angiogenesis inhibitors in clinical development pose challenges
for phase I/II trial design. Because they reduce tumour growth or
prevent metastases through primarily cytostatic modes of action
such as, selectively inhibiting membrane receptors, cell cycle
regulators or other signalling pathways, conventional end points
based on reduction in tumour size may be inadequate for
evaluating clinical response. Alternative imaging biomarkers of
angiogenesis are being sought, which can serve as early indicators
of drug activity in clinical trials and may facilitate early
pharmacodynamic assessments by speeding up the go/no-go
decision-making process (Jayson and Waterton, 2005).
Dynamic contrast-enhanced magnetic resonance imaging mea-
surements have been incorporated as biomarkers of drug efficacy
in clinical trials of angiogenesis inhibitors. The technique is
promising, but its practical application is far from straightforward.
The various analysis methods employed have considerable
influence on the interpretation of derived parameters and their
value as potential biomarkers and/or surrogate end points (Parker
and Buckley, 2005). In this review, we outline the requirements of
imaging biomarkers for clinical trials of novel agents and highlight
relevant features of T1-weighted DCE-MRI that should be
considered when implementing the technique in human studies.
We then assess the clinical findings to date and outline future
directions for DCE-MRI in anticancer drug development.
GENERAL PRINCIPLES OF T1-WEIGHTED DCE-MRI IN
CLINICAL TRIALS
Dynamic contrast-enhanced magnetic resonance imaging is a
noninvasive quantitative method of investigating microvascular
structure and function by tracking the pharmacokinetics
of injected low-molecular weight contrast agents as they pass
through the tumour vasculature. The technique is sensitive to
alterations in vascular permeability, extracellular extravascular
and vascular volumes, and in blood flow (F). It does not involve
ionising radiation, provides good spatial resolution and can be
performed on standard specification 1.5Tesla clinical systems. In
this respect, MRI has practical advantages over computed
tomography (CT) and positron emission tomography (PET) in
evaluating angiogenesis.
In T1-weighted DCE-MRI, an intravenous bolus of gadolinium
contrast agent enters tumour arterioles, passes through capillary
beds and then drains via tumour veins. Gadolinium ions are
paramagnetic and interact with nearby hydrogen nuclei to shorten
T1-relaxation times in local tissue water. This causes increase in
signal intensity on T1-weighted images to a variable extent within
each voxel. The degree of signal enhancement is dependent on
physiological and physical factors, including tissue perfusion,
arterial input function (AIF) (AIF: the concentration-time course
of contrast agent in the artery supplying the vascular bed),
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www.bjcancer.comcapillary surface area, capillary permeability and the volume of
the extracellular extravascular leakage space (EES). T1-weighted
DCE-MRI analysis generates parameters that represent one of, or
combinations of these processes, and can be used to measure
abnormalities in tumour vessel flow, blood volume, permeability,
tortuosity and interstitial pressure (Figure 1). However signal
enhancement will also be affected by contrast agent dose, the
native T1-relaxation time of each tissue and choice of imaging
sequences.
Dynamic contrast-enhanced magnetic resonance imaging
strategies vary, but, in general, three types of imaging data are
acquired. Initial images localise the tumour and provide anatomi-
cal information. Next, sequences that allow calculation of baseline
tissue T1-values before contrast agent administration are acquired
to enable subsequent analysis. Finally, dynamic data are acquired
every few seconds in T1-weighted images over a period of around
5–10min. Dynamic sequences are subject to innate trade-offs
between spatial resolution, temporal resolution (how quickly each
image is acquired) and anatomical coverage. Fast T1-weighted
spoiled gradient echo sequences are generally used as they allow
good contrast medium sensitivity, high signal-to-noise ratio,
adequate anatomical coverage and rapid data acquisition (Parker
and Buckley, 2005).
IMPORTANT CONSIDERATIONS FOR IMAGE
ACQUISTION AND ANALYSIS
Comprehensive discussion of the technical aspects of DCE-MRI
image acquisition and analysis is beyond the scope of this paper.
However, some factors are briefly considered as selection of MRI
sequences and data analysis methods determine not only the range
of parameters available, but also their precise meaning.
Analysis: descriptive or physiological?
Several analysis methods can be applied to DCE-MRI data.
Features of the signal intensity–time curve (e.g. gradient,
overall shape, time to 90% maximum enhancement) represent
simple descriptions of contrast agent distribution. However, these
measures show considerable variation between acquisition method
and individual examinations, making direct comparison between
patients and trials difficult. Conversion of signal intensity into
contrast agent concentration data allows more robust analysis of
contrast agent kinetics. However, unlike dynamic CT or PET, the
relationship between signal intensity and contrast agent concen-
tration is not linear, making conversion of the signal intensity data
far from straightforward (Tofts et al, 1999; Parker and Buckley,
2005).
Parameters that describe the shape of the contrast agent
concentration–time curve represent a combination of flow, blood
volume, vessel permeability and EES volume. One such quantity,
the initial area under the contrast agent concentration–time curve
(IAUC) is easy to calculate (model-free), reasonably reproducible
and is routinely used as a biomarker in drugs trials. However,
IAUC has a complicated and incompletely defined relationship
with underlying tumour physiology and represents a composite of
physiological processes (Tofts et al, 1999).
Which model should be used?
Pharmacokinetic models can be applied to contrast agent
concentration data to enable estimates of physiological character-
istics such as flow and capillary endothelial permeability. Modelled
parameters are in theory more ‘physiologically meaningful’ than
simple descriptors, such as IAUC, and are independent of
acquisition protocol and solely reflect tissue characteristics. Thus,
they are suitable measurements for multicentre studies with
variation in image acquisition protocols and equipments (Leach
et al, 2005).
Consensus opinion recommends that simple models describing
the volume transfer coefficient of contrast between the blood
plasma and the EES (K
trans) and the size of the EES (ve) should be
used along with IAUC in assessing antiangiogenic and vascular
disrupting agents in clinical trials (Leach et al, 2005). Other related
measures such as the rate constant (kep), which describes the ratio
of K
trans/ve have also been used. Several models have been applied
to clinical trial data to enable calculation of K
trans and ve, many of
which are equivalent (Larsson et al, 1990; Tofts and Kermode,
1991).
Changes in F, endothelial permeability and endothelial surface
area produce changes in measurements of K
trans (or an equivalent
parameter, such as Ki) in these models, and the specific
contribution of the individual components cannot be identified.
Importantly, the interpretation of K
trans varies depending on the
relationship between F and capillary permeability–surface area
product (PS). When tissue contrast delivery is ample (FbPS) K
trans
represents the PS per unit volume of tissue, for trans-endothelial
transport between plasma and EES (K
transBPS). In limited
perfusion (PSbF) K
trans represents the F per unit volume of tissue
(K
transBF) (Tofts et al, 1999). In these simple models, both K
trans
and ve calculation are relatively stable but lack physiological
specificity.
Extensions of this model (Tofts 1997) are more complex, but
enable calculation of blood plasma volume (vp) and provide more
accurate estimations of K
trans and ve. More comprehensive models
allow direct quantification of flow (F), extraction fraction (E), ve
and mean capillary transit time (t) (St Lawrence and Lee, 1998).
Here, rather than defining the composite parameter K
trans,i ti s
possible to separate F and PS. However successful application of
this model requires a temporal resolution in the order of 1s to
measure t accurately, which limits its application in clinical trials
(Jayson et al, 2005; Parker and Buckley, 2005).
K
trans does not purely measure capillary permeability in any of
these models (although it is often assumed to do so). Instead, its
exact meaning depends on the kinetic model used for analysis.
Changes in K
trans may also represent different physiological
ve
vi
PS
Blood fow
vp
Figure 1 Compartmental modelling of the tumour microvasculature:
blood flows through the tumour enabling contrast media molecules
(represented as black dots) to distribute in two potential compartments –
the blood plasma volume vp and the volume of the extravascular
extracellular space ve. Clinically available MRI contrast agents do not leak
into the intracellular space vi. Contrast agent leakage is governed by the
concentration difference between the plasma and the extracellular
extravascular space and by the permeability and surface area of the
capillary endothelia, expressed as PS.
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(e.g. reduction in K
trans could represent reduced flow, reduced
permeability or a combination of the two). The choice of analysis
techniques is therefore not straightforward and reflects a
compromise between parameters that are either relatively simple
but poorly specific or physiologically congruent but less stable.
Imaging protocol
Incorporating DCE-MRI into clinical trials has required consider-
able technical expertise from basic scientists and clinicians in
preparing nonstandard MRI sequences and in-house software for
data analysis. Hence, early DCE-MRI studies varied in data
acquisition and analysis methods, making comparison difficult
and confusing. Multicentre trials require uniform image acquisi-
tion and analysis favouring reproducible machine-independent
protocols. Such studies require careful quality control and are
increasingly managed by contract research organisations specialis-
ing in advanced imaging applications. Multicentre DCE-MRI trial
feasibility has been demonstrated by studies of the tyrosine kinase
inhibitors AG-013736 (Liu et al, 2005) and BIBF 1120 (Padhani
et al, 2006). At present, two baseline scans are recommended for all
studies (to define parameter reproducibility) (Leach et al, 2005),
but guidelines on the timing of MRI scanning and the choice of
imaging parameters are less clear.
Importance of the AIF
In theory, the models described above require direct measurement
of an AIF along with the tumour contrast agent concentration–
time course curve. These two functions are then used to
quantify the passage of contrast agent through the tumour.
Ideally, the AIF should be measured for each examination, as it
varies between individuals and visits reflecting physiological
variation in cardiac output, vascular tone, renal function
and injection timing. Unfortunately, AIF measurement is
technically demanding and, at best, produces an indirect
measurement from a nearby large artery that may differ from
the vessel supplying the tumour. Therefore, many groups use an
idealised mathematical function instead, which allows far greater
freedom in the imaging protocol by relaxing requirements on
temporal resolution, slice positioning and sequence choice, but
makes no attempt to reflect the true blood supply to the tumour at
each examination (Parker and Buckley, 2005). Whichever techni-
que is used, AIF measurement has a major impact on data analysis
and clinical results – inaccuracy in the form or scale of the AIF
affects the magnitude of all of the modelled parameters and their
reproducibility.
Region of interest and statistical analysis
Data analysis is performed on a defined region of interest (ROI)
that encompasses all or part of the tumour. A single average-
enhancement curve can be extracted and used to generate values
of parameters of interest (such as IAUC or K
trans), and the same
parameters can then be compared following therapy (Dowlati et al,
2002; Morgan et al, 2003; Liu et al, 2005; Mross et al, 2005a;
Thomas et al, 2005). This method ignores heterogeneity within
the tumour. Alternatively, data can be extracted from each voxel
within the ROI and summary statistics such as the mean and s.d.,
or median and interquartile range may be calculated (Jayson et al,
2002, 2005; Galbraith et al, 2003; Evelhoch et al, 2004). This second
method can describe both normal and nonnormal data distribu-
tions and provides limited information regarding microvascular
heterogeneity. In practice, both methods have been used in trials of
antiangiogenic and vascular disrupting agents.
Data quality
Established and agreed policies for quality control are essential.
T1-values should be checked against a reference range for the
relevant magnetic field strength. Significant motion artefact, AIF
and ROI definition and signal-to-noise ratio should be assessed
and corrected. If correction is not possible, then corrupted datasets
should be removed from subsequent analysis (Buonaccorsi et al,
2006). These considerations are important because they influence
the accuracy of data (hence ensure quality control) and the
significance/power of results (hence avoid dataset exclusion). In
practice data are frequently suboptimal and can lead to trial data
being excluded or of limited value (Eder et al, 2002; Morgan et al,
2003; Stevenson et al, 2003; Liu et al, 2005; O’Donnell et al, 2005).
CLINICAL TRIALS TO DATE: METHODS AND
RESULTS
At the time of writing, 21 trials of antiangiogenic compounds (Eder
et al, 2002; Jayson et al, 2002, 2005; Morgan et al, 2003; Thomas
et al, 2003, 2005; Conrad et al, 2004; Medved et al, 2004;
Overmoyer et al, 2004; Xiong et al, 2004; Drevs et al, 2005; Liu
et al, 2005; Mross et al, 2005a,b; O’Donnell et al, 2005; O’Dwyer
et al, 2005; Rosen et al, 2005, 2006; Padhani et al, 2006; Watson
et al, 2006; Wedam et al, 2006) and six trials of vascular disrupting
compounds (Dowlati et al, 2002; Galbraith et al, 2002, 2003;
Stevenson et al, 2003; Evelhoch et al, 2004; McKeage et al, 2006)
have employed T1-weighted DCE-MRI analysis and described their
protocols and findings in enough detail to allow critical appraisal
(Tables 1 and 2). Most were small cohort single-centre phase I
trials in patients with advanced solid tumours, although a small
number of phase II trials have incorporated DCE-MRI (Wedam
et al, 2006). Marked variation in tumour size (Evelhoch et al,
2004), anatomy and pathophysiology and previous treatment
(Morgan et al, 2003) have made data evaluation difficult and may
have masked subtle drug effects, prompting a move towards
stricter inclusion criteria (Morgan et al, 2003; Mross et al, 2005a;
O’Dwyer et al, 2005) or using an intra-patient dose escalation
design (Jayson et al, 2002; Stevenson et al, 2003).
Biomarker evidence of drug effect – what does it mean?
Dynamic contrast-enhanced magnetic resonance imaging para-
meters are subject to random error, biological variation and
systemic inaccuracies that cause day-to-day variation in measured
values. Many investigators consider a change in K
trans of X40% as
likely to represent a true difference in the parameter as some
evidence suggests it correlates with disease stability/response, but
in practice the confidence interval for each parameter depends on
the choice of model, AIF methods and ROI definition (Roberts
et al, 2006). Knowing the intrapatient variability for the study
population is essential to have confidence that a parameter change
is due to drug effect. Therefore, many (though not all) centres
perform two baseline scans to measure reproducibility for each
trial dataset, in accordance with published guidelines (Galbraith
et al, 2003; Jayson et al, 2005; Padhani et al, 2006).
Evidence of drug efficacy has been demonstrated with DCE-MR1
in several trials of antiangiogenic drugs. Significant reductions in
K
trans have been reported in patients with advanced breast cancer
receiving bevacizumab alone, implying reduction in F and/or
permeability. K
trans reduction was increased following a further six
cycles of bevacizumab with conventional chemotherapy. However
changes in K
trans did not predict response rate (RR) (Wedam et al,
2006). Several tyrosine kinase inhibitors, notably AG-013736 (Liu
et al, 2005), BIBF1120 (Mross et al, 2005b) and AZD2171 (Drevs
et al, 2005) have all shown dose-dependent reductions in K
trans and
IAUC without demonstrating clinical response.
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Study Agent N Tumour group
a DCE-MRI biomarker Evidence of drug effect Inform dose Predict outcome
Anti-VEGF antibody
Jayson HuMV833 20 Mixed K
trans, kep, rBV Reduction in Kep but no dose relationship No No
Overmoyer Bevacizumab 26 Breast kep Reduction in Kep ——
Wedam Bevacizumab 20 Breast K
trans, ve k K
trans 34% EC1 (BV alone) & 75% EC7 (BV+ cytotoxic) No dose relationship K
trans did not predict RR
Tyrosine kinase inhibitor
Conrad PTK/ZK 14 GBM Ki, rBV Dose-dependent k Ki B40% at d28 — Ki predicts progression
Morgan PTK/ZK 26 CRC Ki Dose-dependent k Ki – 58% in X 1000mg at d2, 53% at d28 Optimum X1000mg Ki predicts RR & progression
Mross PTK/ZK 27 CRC/Breast Ki Dose-dependent k Ki – 54% in X1000mg at d2, 51% at d28 Optimum X1000mg Ki predicts RR & progression
Thomas PTK/ZK 35 Mixed Ki Dose-dependent k Ki – 46% in X1000mg at d2, 40% at d28 Optimum X1000mg Ki predicts RR & progression
Drevs AZD2171 24 Mixed IAUC k IAUC of X40% in five out of seven patients Effective 20–45mg —
Medved SU 5146 19 Mixed IAUC Progressive disease despite k IAUC — —
O’Donnell SU 5146 24 Mixed K
trans, ve No consistent relationship with clinical measures No dose relationship —
Liu AG-013736 17 Mixed IAUC, K
trans Dose-dependent k IAUC, K
trans d2 and d28. Effect lost d56 — —
O’Dwyer BAY 43-9006 12 Renal CC K
trans, ve Mean reduction K
trans 61% K
trans predicts RR & PFS
Rosen AMG-706 18 Mixed IAUC k IAUC of p61% — —
Rosen BMS-582664 7 Mixed K
trans k K
trans X40% in 600–800mg cohort Effective 600–800mg —
Xiong SU6668 4 Mixed IAUC, slope None No No
Mross BIBF1120 27 Mixed IAUC, Ki Reduced IAUC & Ki X40% in higher dose groups No —
Padhani BIBF1120 35 Mixed IAUC, K
trans, kep No consistent relationship with clinical measures No —
Anti-PDGFR-b antibody Fab’
Jayson CDP860 8 CRC/Ovary IAUC, K
trans, ve, vp m vascularised tumour volume in some patients No No
Recombinant human endostatin
Eder rhEndostatin 10 Mixed K
trans, ve None No No correlation with PFS or OS
Thomas rhEndostatin 21 Mixed No detail provided None No No correlation with TTP
Anti-av integrin
Watson CNTO95 22 Mixed IAUC, K
trans, ve, vp No consistent relationship with clinical measures No —
CRC¼colorectal; d¼day; DCE-MRI¼Dynamic contrast-enhanced magnetic resonance imaging; EC¼end cycle; GBM¼glioblastoma multiforme; IAUC¼initial area under the contrast agent concentration–time curve; Ki ¼uni-
directional influx constant; kep¼rate constant; K
trans¼bi-directional transfer co-efficient; OS¼overall survival; PDGFR¼platelet-derived growth factor receptor; PFS¼progression-free survival; rBV¼regional blood volume; Renal
CC¼renal cell carcinoma; RR¼response rate; slope¼slope of the uptake curve; TTP¼time to progression; VEGF¼vascular endothelial growth factor; ve¼volume of the EES; vp¼blood plasma volume
aTumours were either
mixed solid group, or breast, glioblastoma multiforme (GBM), colorectal (CRC), renal cell carcinoma (Renal CC) or epithelial ovarian (Ovary).
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KFew trials have demonstrated a relationship between DCE-MRI
biomarker and clinical outcome measure. Correlation of K
trans
reduction and RR and progression-free survival (PFS) has been
shown with BAY 43-9006 (O’Dwyer et al, 2005). Reduction, in Ki of
X40% has predicted which patients progressed with glioblastoma
multiforme in a trial of PTK787/ZK222584 (PTK/ZK) (Conrad
et al, 2004). Changes in K
trans following trials of AZD2171 (Drevs
et al, 2005) and BMS-582664 (Rosen et al, 2006) have helped define
the effective dose to take into phase II studies.
The studies outlined above show that DCE-MRI biomarkers can
provide early indicators of efficacy, dose and outcome. However,
such findings do not guarantee success in phase III development.
Three related trials of PTK/ZK reported promising early results
with DCE-MRI biomarkers. Patients with colorectal carcinoma
liver metastases (mixture of disease stage and extent of prior
therapy) showed a dose-dependent reduction in Ki of 43% at day 2,
which was greatest in higher-dose groups (X1000mg once daily),
where Ki was reduced by 58% on day 2 and 53% at the end of cycle
1 (EC1). Reduction in tumour enhancement at day 2 and EC1
(measured by reduction in Ki from baseline) predicted disease
progression and was positively correlated with reduction in
tumour size (Morgan et al, 2003). Statistically significant dose-
dependent changes in Ki from baseline at day 2 and day 28 were
identified in two subsequent studies of PTK/ZK in patients with
mixed solid tumours (X1000mg once daily) (Mross et al, 2005a;
Thomas et al, 2005). A biologically active dose of 1000mg was
identified in all three studies.
Two subsequent randomised phase III trials of PTK/ZK with
standard treatment in patients with metastatic colorectal carcino-
ma suggest that DCE-MRI parameter changes may be necessary
but not sufficient biomarkers of drug efficacy. Oral PTK/ZK
(1250mg q.d.s) or placebo were administered with oxaloplatin/
5-flurouracil/leucovorin (FOLFOX4) as first-line (CONFIRM-1)
(Hecht et al, 2005) or second-line therapy (CONFIRM-2) (Koehne
et al, 2006). Analysis of PFS in CONFIRM-1 did not achieve
statistical significance. Overall survival (OS) data are awaited.
Response rate between trial arms were not significantly different
and the primary endpoint of OS was not met in CONFIRM-2,
although PFS was significantly longer in the PTK/ZK arm (5.5 vs
4.1 months; hazard ratio 0.83; P¼0.026).
Fewer trials of vascular disrupting agents have incorporated
DCE-MRI biomarkers. Evidence of drug efficacy has been shown in
the flavonoid DMXAA (Galbraith et al, 2002), the antitubulin agent
CA-4-P (Galbraith et al, 2003) and the colchicine analogue ZD6126
(Evelhoch et al, 2004). Evaluation of CA-4-P helped define the
biologically active and maximum tolerated doses.
Negative results – how confident are we?
Three factors are imperative if DCE-MRI biomarkers are to detect
true negative results and hence increase the value of DCE-MRI in
evaluating antiangiogenic and vascular disrupting agents. Firstly,
correct scan schedule is required. For example, vascular disrupting
agent drug effects are typically seen within hours of administration
and may be lost within 24h. Thus, DCE-MRI trials of vascular
disrupting agents require imaging at baseline, 4–6 and at 24h. In
contrast, antiangiogenic drug effects typically occur within days to
weeks and may persist for weeks to months, so that imaging must
be performed at these time points.
Secondly, correct and robust parameters must be selected for
each compound and used appropriately. Most studies employ
changes in mean or median IAUC and K
trans irrespective of the
proposed drug mechanism. Although changes in K
trans may be
meaningful in trials of VEGF/VEGF-receptor inhibitors, its
usefulness in evaluating other compounds is less clear. Parameters,
such as change in relative enhancing fraction within the
total tumour volume, influenced by altered interstitial pressure,
may be more informative in assessment of platelet-derived growth
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et al, 2005). Parameter changes require correct interpretation, as
for example K
trans changes may reflect altered flow or vascular
permeability. Data quality (minimal motion, well-defined AIF and
reproducible analysis) must be sufficient to allow measured
parameters changes to be detected.
Finally, data analysis is crucial and must be critically appraised
in each trial. Current methods that produce summary parameters
oversimplify data and may mask critical information concerning
tumour heterogeneity. Alternative methods of data evaluation,
such as histogram analysis (Watson et al, 2006) may have a role in
demonstrating changes in heterogeneity. Equally, tumour sub-
regions may require separate analysis in order to detect subtle
drug effects (e.g. rim-core differential of vascular disrupting agent
action) (Walker-Samuel et al, 2006), which may otherwise be
obscured and be reported as false negative results.
CONCLUSIONS AND FUTURE CHALLENGES
Magnetic resonance imaging biomarkers of tumour angiogenesis
require validation, ideally against clinical outcome measures such
as OS, PFS or RR. At present, an insufficient number of clinical
studies have correlated changes in K
trans, IAUC or other DCE-MRI
biomarkers with clinical outcome to allow their adoption as
established surrogate end points of drug effects. Validation against
histopathology biomarkers such as microvascular density is
problematic in DCE-MRI, where micrometer scale biopsy changes
must be compared against voxel resolution in millimetres.
Nonetheless, histopathology validation is important and can
substantiate the use of a biomarker in phase I/II trials. Both
animal models and clinical studies are likely to be required to
achieve comprehensive validation (Jayson and Waterton, 2005;
Leach et al, 2005).
Dynamic contrast-enhanced magnetic resonance imaging is
considerably more complex than conventional anatomical ima-
ging. Acquisition and analysis protocols place a significant
demand on both patients and staff. However, initial studies show
that the technique is feasible, and T1-weighted DCE-MRI
parameters have provided considerable noninvasive information
concerning tumour biology and response to treatment. Future
developments in image acquisition and analysis are evolving
rapidly and may further increase the potential that DCE-MRI has
to play in future assessment, diagnosis and follow-up of cancer.
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